KRT13
Reactivity: Human
WB, ELISA
Host: Mouse
Monoclonal
4F5
unconjugated
Application Notes
Optimal dilution of the recombinant KRT13 antibody should be determined by the researcher.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
1 mg/mL in 1X PBS, BSA free, sodium azide free
Preservative
Azide free
Storage
-20 °C
Storage Comment
Aliquot the recombinant KRT13 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
Target
Cytokeratin 13 (KRT13)
(Keratin 13 (KRT13))
Alternative Name
KRT13
Background
Cytokeratins comprise a diverse group of intermediate filament proteins (IFPs)that are expressed as pairs in both keratinized and non-keratinized epithelial tissue. Cytokeratins play a critical role in differentiation and tissue specialization and function to maintain the overall structural integrity of epithelial cells. Cytokeratins have been found to be useful markers of tissue differentiation, which is directly applicable to the characterization of malignant tumors. Cytokeratins 10 and 13 are present in the cytoskeletal region of a subset of squamous cell carcinomas. Cytokeratin 13 belongs to the intermediate filament family and is a heterotetramer of two type I acidic and two type II basic keratins. It is generally associated with Cytokeratin 4. Defects in the KRT13 gene are a cause of white sponge nevus of cannon (WSN), a rare autosomal dominant disorder which predominantly affects noncornified stratified squamous epithelia and is characterized by the presence of soft, white and spongy plaques in the oral mucosa.